Arrowhead Pharmaceuticals, Inc. Common Stock Earnings Dividend

Arrowhead Pharmaceuticals, Inc. Common Stock’s revenue jumped 171.02% since last year same period to $75.25Mn in the Q2 2026. On a quarterly growth basis, Arrowhead Pharmaceuticals, Inc. Common Stock has generated 2.06% jump in its revenue since last 3-months.

Arrowhead Pharmaceuticals, Inc. Common Stock’s net profit fell -10.86% since last year same period to $-194.28Mn in the Q2 2026. On a quarterly growth basis, Arrowhead Pharmaceuticals, Inc. Common Stock has generated -46.37% fall in its net profits since last 3-months.

Arrowhead Pharmaceuticals, Inc. Common Stock’s net profit margin jumped 59.09% since last year same period to -258.17% in the Q2 2026. On a quarterly growth basis, Arrowhead Pharmaceuticals, Inc. Common Stock has generated -43.42% fall in its net profit margins since last 3-months.

Arrowhead Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -1.23 - a -10.81% fall from last quarter’s estimates.

Arrowhead Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -1.23.

Arrowhead Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) fell -7.94% since last year same period to -1.36 in the Q2 2026. This indicates that the Arrowhead Pharmaceuticals, Inc. Common Stock has generated -7.94% annual rate of fall in its earning per share (EPS) in the last 4 quarters.